SAKAR
Sakar Healthcare Limited
Each stock's 10,000-path forecast, rendered as light.
Sakar Healthcare Limited (SAKAR) Stock Analysis & Case Study
Is SAKAR a good buy? The data-driven verdict.
Sakar Healthcare Limited (SAKAR) trades at ₹925,on the numbers it high-risk on the numbers, a Downstox Snapshot Score of 28/100.
On the numbers, Sakar Healthcare Limited (SAKAR) high-risk on the numbers, a Downstox Snapshot Score of 28/100, weighing expensive at 57.0× earnings, ROE of 10.0%, a 52% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
SAKAR fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How SAKAR ranks against the 2,373 companies in our screener
- SAKAR's market cap of 2,057 Cr ranks in the 51st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SAKAR's book value of ₹146 ranks in the 63rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SAKAR's promoter holding of 52.5% ranks in the 36th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SAKAR's 3-year profit (PAT) growth of 34.0% ranks in the 73rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SAKAR's 3-year revenue growth of 24.0% ranks in the 79th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SAKAR's debt-to-equity ratio of 0.17x is lower than 66% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is SAKAR overvalued? SAKAR P/E vs peers
SAKAR trades at 57.0× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
SAKAR share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.2y of SAKAR history (30%/yr drift, 46%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| SAKAR 2027 | ₹528 | ₹947 | ₹1,697 | +2% |
| SAKAR 2028 | ₹421 | ₹970 | ₹2,233 | +5% |
| SAKAR 2029 | ₹360 | ₹993 | ₹2,735 | +7% |
| SAKAR 2030 | ₹318 | ₹1,017 | ₹3,252 | +10% |
| SAKAR 2031 | ₹281 | ₹1,041 | ₹3,852 | +13% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability SAKAR goes up, or doubles?
The bull case for SAKAR
- Sakar Healthcare Limited is part of the nifty500 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹2,735.
The bear case & risks
- SAKAR's P/E of 57.0x is lower than 23% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SAKAR's return on equity of 10.0% ranks in the 48th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- High historical volatility (46%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹360.
SAKAR volatility & expected range, how bumpy is the ride?
Over the last 9.2 years SAKAR compounded at 30%/year with annualized volatility of 46%. That volatility implies a 1-year 80% range of ₹528-₹1,697, the honest backbone behind any single price target.
SAKAR price forecast, the full 60-month probability fan
SAKAR price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds SAKAR hits common targets within the simulated horizon?
Full multi-horizon detail on the SAKAR price target & forecast page.
SAKAR Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. SAKAR scores 5/8, mixed financial health.
SAKAR MTF margin & leverage across 7 brokers
Margin Trading Facility lets you buy SAKAR with part of the capital. Lower margin % = higher leverage. Rates compared across 7 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 38.57% | 2.6× |
| ZerodhaCHEAPEST | 38.51% | 2.6× |
| Dhan | 50.00% | 2.0× |
| Kotak Neo | 100.00% | 1.0× |
| Paytm Money | 38.68% | 2.6× |
| Pocketful | 38.77% | 2.6× |
| Share India | 38.64% | 2.6× |
Compare every broker on the SAKAR MTF page.
About Sakar Healthcare Limited: sector, index & market-cap context
Sakar Healthcare Limited (SAKAR) is a small-cap NSE-listed company, with a market capitalisation of ₹2,057 Cr. See more stocks on our screener.
How the SAKAR Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Sakar Healthcare Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
SAKAR analysis, FAQs
Is Sakar Healthcare Limited (SAKAR) a good buy?
On the numbers, Sakar Healthcare Limited (SAKAR) high-risk on the numbers, a Downstox Snapshot Score of 28/100, weighing expensive at 57.0× earnings, ROE of 10.0%, a 52% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is SAKAR overvalued or undervalued?
SAKAR trades at 57.0× earnings, expensive versus the ~22× long-run Nifty average.
What is the SAKAR share price target for 2031?
SAKAR's probability-weighted 2031 median target is ₹1,041, with an 80% range of ₹281-₹3,852 (10,000-path Monte-Carlo).
What is the probability SAKAR doubles in 5 years?
The modelled probability of SAKAR reaching ₹1,849 (2×) within 5 years is 29%.
What is the bull case for SAKAR?
Sakar Healthcare Limited is part of the nifty500 universe with live, tracked fundamentals on Downstox.
What are the risks in SAKAR?
SAKAR's P/E of 57.0x is lower than 23% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. SAKAR's return on equity of 10.0% ranks in the 48th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. High historical volatility (46%/yr) means a wide, bumpy range of outcomes, size positions accordingly.